BioMarin To Acquire Inozyme Pharma For $270M, Bolstering Rare Disease Portfolio With INZ-701

BioMarin Pharmaceutical has announced a definitive agreement to acquire Inozyme Pharma for approximately $270 million, or $4.00 per share in an all-cash deal. The acquisition has received unanimous approval from both companies’ Boards and is anticipated to close in Q3 2025, pending regulatory clearances, the success of a tender offer, and other standard closing conditions. The deal expands BioMarin’s enzyme therapy portfolio by adding INZ-701, Inozyme’s late-stage enzyme replacement therapy candidate. 

"BioMarin has been deeply committed to advancing enzyme therapies for children and adults living with serious genetic conditions for more than 25 years, and today's agreement builds on our legacy. This acquisition brings to BioMarin an important medicine that has the potential to be the first treatment for children and adults with ENPP1 Deficiency, improving care for people living with this serious condition. As BioMarin continues our transformation and delivers on our corporate strategy, we will continue to evaluate external innovation alongside internal innovation. We are in a strong financial position to bring in additional assets as we accelerate the development of medicines for patients with significant unmet need," said Alexander Hardy, President and Chief Executive Officer of BioMarin.

INZ-701 is currently in development for treating ENPP1 Deficiency, a rare and life-threatening genetic disorder that severely affects vascular, skeletal, and soft tissues. The condition carries high cardiovascular risk, especially in infants, and causes debilitating bone disease in children and adults. BioMarin views the acquisition as a strategic complement to its rare disease pipeline. With Phase 3 data for pediatric patients expected in early 2026, BioMarin aims to pursue regulatory approval by 2027. 

"Today's announcement gives greater hope to patients who may benefit from INZ-701, a potentially transformative therapy that aims to address the underlying causes and systemic impacts of ENPP1 Deficiency. BioMarin has paved the way over the past two and a half decades, successfully launching five first-in-disease enzyme therapies. I'd like to thank the team at Inozyme and our partners for their outstanding work and dedication, as we pass this important potentially life-changing therapy to the leading innovator in genetically defined conditions," commented Douglas A. Treco, Ph.D., Chief Executive Officer and Chairman of Inozyme.